BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Iberia Pharma set to open manufacturing unit in India with investment of Rs 70 Cr

31 July 2025 | News

The company plans to generate 600+ jobs in this facility



Gurugram-based Iberia Pharmaceuticals has announced its new hi-tech manufacturing and research facility spread across 60000 sq. ft. in Jhajjar, Haryana. The next-generation unit is expected to be operational by mid of 2026.

The facility is designed to serve customers with science-baked, derma-driven, wellness products. The company has made a massive investment of Rs 70 crore and is proud to be a part of the government backed ‘Make-in-India’ movement.

This unit is equipped with best-in-class control systems and equipment. The facility will be supported by an experienced team that will be committed to ensuring large-scale commercial manufacturing is carried on smoothly. The scale of manufacturing will not compromise on international standards of quality control. The plant will focus on delivering economically viable solutions, in a robust, compliant, and environmentally sustainable manner. The idea is to support customers who are seeking highly effective, and personalised skin-care products.

Overall, with a focus on research and development, the high-tech research laboratories will support continuous tracking of market, consumer demand, product development, and judicious formulation improvement, all of which will be grounded in real-world science.

At full scale, this manufacturing unit will make more than 12 million units a year in the areas of dermatology, wellness and chronic care for the Indian and global markets. The company will also generate 600+ jobs in this facility.

Iberia Pharmaceuticals brings clinically tested, globally trusted brands to Indian consumers, including Sesderma, Mediderma, Dermpix, Noreva, Metacare amongst other respected brands.